How big is the chikungunya market today, and what are its future growth expectations?
The chikungunya market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.65 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing per capita healthcare expenditures, growing prevalence of emerging and re-emerging infectious diseases, increasing personal disposable income, climate change, and increasing awareness regarding mosquito disease.
The chikungunya market size is expected to see strong growth in the next few years. It will grow to $0.93 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to an international boost in clinical trials, a growing geriatric population, a rising need for immunization, increasing government and non-government initiatives, increasing government investments, and favorable policies. Major trends in the forecast period include advancements in biotechnology for vaccine development, new vaccine opportunities, CRISPR and AI for innovative solutions, strategic collaborations among pharmaceutical players, and integration of telemedicine services.
Get Your Free Sample of The Global Chikungunya Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp
What have been the primary factors driving the chikungunya market’s growth?
The rising prevalence of mosquito-borne diseases is expected to propel the growth of the chikungunya market going forward. Mosquito-borne diseases, such as chikungunya, dengue, and zika virus, are transmitted to humans by infected aedes mosquitoes and pose significant public health challenges globally. The rising global incidence of mosquito-borne diseases is due to climate change, urbanization, deforestation, stagnant water accumulation, inadequate vector control measures, increased global travel, and insecticide resistance. Chikungunya treatment supports mosquito-borne disease patients by alleviating symptoms such as fever, joint pain, and inflammation, improving overall comfort and mobility, reducing the risk of complications, and enhancing recovery through hydration, pain management, and supportive care. For instance, in December 2024, according to the UK Health Security Agency, a UK-based government agency, Between January and June 2024, reported dengue cases among returning travelers in England, Wales, and Northern Ireland surged to 473, marking a 201% increase compared to the 157 cases recorded during the same period in 2023. Therefore, the increasing global incidence of mosquito-borne diseases is driving the growth of the chikungunya market.
What are the key segments within the chikungunya market?
The chikungunya market covered in this report is segmented –
1) By Type: Antiviral Drugs, Herbal And Complementary Treatments, Supportive Care, Vaccines
2) By Product Form: Liquid Form, Powder, Solid Form
3) By Disease Stage: Acute, Chronic, Post-Infection
4) By Sales Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Supermarkets
5) By End User: Caregivers, Healthcare Professionals, Patients
Subsegments:
1) By Antiviral Drugs: Nucleoside Analogues, Protease Inhibitors
2) By Herbal And Complementary Treatments: Ayurvedic Remedies, Homeopathic Treatments, Traditional Chinese Medicine
3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen), Fluid Therapy, Physiotherapy
4) By Vaccines: Live-Attenuated Vaccines, Inactivated Vaccines, mRNA-Based Vaccines
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report
Which key players are shaping the chikungunya market?
Major companies operating in the chikungunya market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Quest Diagnostics Incorporated, Eurofins Scientific SE, Grifols Diagnostic Solutions Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Euroimmun AG, Evotec SE, Valneva SE, ELITechGroup S.A.S., Vaxart Inc., BioPerfectus Biotechnology Co. Ltd., CTK Biotech Inc., Creative Diagnostics Inc., Inovio Pharmaceuticals Inc., Biotrol Laboratories Pvt. Ltd.
How will emerging trends drive the chikungunya market throughout the forecast period?
Major companies operating in the chikungunya market are focusing on developing innovative vaccines to enhance immunity, prevent disease outbreaks, and address the growing global health burden of chikungunya virus infections. A live attenuated chikungunya vaccine is a vaccine that uses a weakened form of the chikungunya virus to stimulate an immune response without causing the disease, providing long-lasting protection. For instance, in November 2023, Valneva SE, a France-based biotechnology company announced IXCHIQ, a live attenuated chikungunya vaccine approved by the Food and Drug Administration (FDA), a US-based government agency. This approval was made under accelerated approval based on anti-CHIKV neutralizing antibody titers, with continued approval contingent upon verification of clinical benefit in confirmatory studies. Valneva received a Priority Review Voucher (PRV) from the FDA, which the company intends to monetize to help finance its research and development programs. Ixchiq is given as a single-dose injection into the muscle and contains a live, weakened form of the chikungunya virus, which may cause symptoms in recipients similar to those of chikungunya disease.
How do regional factors impact the chikungunya market, and which region is the largest contributor?
North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Chikungunya Market Report 2025 Offer?
The chikungunya market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Chikungunya (CHIKV) is a viral infection caused by the chikungunya virus, primarily transmitted to humans through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. The virus causes fever, joint pain, headache, rash, and muscle pain, significantly impacting the quality of life of affected individuals.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21137
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
